In the study, researchers performed the kind of deeply intricate computational genomics needed to both interpret and translate the signatures that each cancer drug had left in the genome. The Nature study exemplifies Precision Child Health, combining genomic information with treatment history to better understand how a therapy could affect a patient's cancer over time and adjust treatment to potentially reduce toxic effects. “When we treat it with chemotherapy, the interaction between tumour and treatment changes its makeup and evolutionary pathway. Researchers say the genomic signatures identified in the study may, in the future, act as biomarkers to create a potential early warning system for children undergoing cancer treatment. In the future, that could mean a blood test for patients of any age who face the need for chemotherapy.